Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 7/20 | 0.49 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL28584252 | 0.89 | S1PR3 (0.52) | S1PR3VCAM1ALDH1A1KDM4ES1PR1 | |
| SCHEMBL10817523 | 0.87 | S1PR3 (0.48) | S1PR3VCAM1ALDH1A1KDM4EIDH1 | |
| SCHEMBL102792 | 0.82 | TSHR (0.48) | S1PR3VCAM1TSHRMAOAMAOB | |
| SCHEMBL13307710 | 0.81 | FFAR1 (0.53) | VCAM1TSHRCYP2A6CYP3A4 | |
| SCHEMBL7050401 | 0.78 | MAOA (0.61) | VCAM1MAOAMAOBALDH1A1KDM4E | |
| SCHEMBL31441456 | 0.78 | MAOA (0.61) | VCAM1MAOAMAOBALDH1A1KDM4E | |
| SCHEMBL8404523 | 0.78 | GPR35 (0.46) | S1PR3VCAM1TSHRMAOAMAOB | |
| SCHEMBL8269230 | 0.78 | GPR35 (0.46) | S1PR3VCAM1TSHRMAOAMAOB | |
| SCHEMBL5127052 | 0.77 | FFAR1 (0.43) | S1PR3VCAM1TSHRALDH1A1KDM4E | |
| SCHEMBL17404394 | 0.77 | CYP3A4 (0.41) | S1PR3TSHRALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132112-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2026-05-14 | — | — | US | disclosed |
| EP-4077318-B1 | BENZIMIDAZOLE DIMERS AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2025-10-15 | — | — | EP | disclosed |
| US-12415785-B2 | Compound modulators of sting | CTXT PTY LTD (AU) | 2025-09-16 | — | — | US | disclosed |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-08-21 | — | — | US | disclosed |
| US-12325697-B2 | CBL-B modulators and uses thereof | NIMBUS CLIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-11 | — | — | US | disclosed |
| CN-114981265-B | Compounds of formula (I) | CTXT私人有限公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-4477220-A2 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-12-18 | — | — | EP | disclosed |
| WO-2024199457-A1 | COMPOUND HAVING RING FUSED STRUCTURE, PREPARATION METHOD THEREFOR AND USE THEREOF, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 苏州安赛隆医药科技有限公司 | 2024-10-03 | — | — | WO | disclosed |
| CN-118724903-A | Compound with fused ring structure, its preparation method and use, and pharmaceutical composition and use | 苏州安赛隆医药科技有限公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2002064559-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-1178802-A1 | CYCLIC AMIDINES USEFUL AS NMDA NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000067755-A1 | CYCLIC AMIDINES USEFUL AS NMDA NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| US-5034410-A | Nitrile and oxo containing amides or thioamides | SYNTEX (U.S.A.) INC. (US) | 1991-07-23 | — | — | US | disclosed |
| US-4344957-A | Benz-acyl-benzimidazole derivatives and antiallergic compositions | CIBA-GEIGY CORPORATION (US) | 1982-08-17 | — | — | US | disclosed |
| US-4269834-A | Copper complexes of isoquinazolines | NAUTA WIJBE T | 1981-05-26 | — | — | US | disclosed |
| US-4244966-A | 1,3-Dihydro-3-(2-hydroxy-, 2-bromo- or 2-chloroethyl)-2H-isoindol-1-one derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-01-13 | — | — | US | disclosed |
| US-4213993-A | ANTIALLERGENS | CIBA-GEIGY CORPORATION (US) | 1980-07-22 | — | — | US | disclosed |
| US-4141982-A | ANTIALLERGENS | CIBA-GEIGY CORPORATION (US) | 1979-02-27 | — | — | US | disclosed |
| US-4029493-A | Substituted phenoxybenzonitriles as herbicides | MOBIL OIL CORPORATION (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | S1PR3 497/4885VCAM1 498/4885TSHR 4025/4885 |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | S1PR3 2418/4885VCAM1 3666/4885TSHR 3636/4885 |
| US-12415785-B2 | Compound modulators of sting | STING1, IRF3, MAVS | S1PR3 1630/4885VCAM1 2507/4885TSHR 4301/4885 |
| US-20260132112-A1 | COMPOUNDS | STING1, IRF3, CGAS | S1PR3 914/4885VCAM1 2109/4885TSHR 1389/4885 |
| US-12325697-B2 | CBL-B modulators and uses thereof | CBLB, CBL, CBLC | S1PR3 2418/4885VCAM1 3666/4885TSHR 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.